1.29%
-4.27%
-19.87%
-32.95%
-21.08%
86.40%
196.48%
AI Spotlight on NOVO
Company Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.It operates in two segments, Diabetes and Obesity care, and Rare Disease.The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.
The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy.The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics.The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Market Data
| Last Price | 611.5 |
| Change Percentage | 1.29% |
| Open | 615.6 |
| Previous Close | 603.7 |
| Market Cap ( Millions) | 2743511 |
| Volume | 1027193 |
| Year High | 1033.2 |
| Year Low | 526 |
| M A 50 | 675.62 |
| M A 200 | 830.78 |
Financial Ratios
| FCF Yield | 2.46% |
| Dividend Yield | 1.62% |
| ROE | 86.40% |
| Debt / Equity | 47.27% |
| Net Debt / EBIDTA | -0.03% |
| Price To Book | 22.6 |
| Price Earnings Ratio | 28.75 |
| Price To FCF | 40.7 |
| Price To sales | 10.14 |
| EV / EBITDA | 19.52 |
News
- 11:37 - Novo Nordisk Shares Have a Long Road Back from 40% Slump
- 09:30 - Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry
- 07:54 - A cautionary tale that Europe can’t afford to ignore
- Jan -30 - Jim Cramer on Novo Nordisk A/S (NVO): ‘They Don’t Have The Production Capability’
- Jan -29 - Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
- Jan -29 - Why Novo Nordisk A/S (NVO) Is the Best Blue Chip Stock to Buy Under $100?
- Jan -29 - Jim Cramer Says Novo Nordisk A/S (NVO) Is ‘Down So Much’
- Jan -29 - AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
- Jan -29 - Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
- Jan -29 - 5 Monster Stocks to Hold for the Next 10 Years
- Jan -28 - Ozempic's FDA Approval Just Sent Shockwaves Through the Kidney Disease Market
- Jan -28 - How to Play NVO Stock After New Drug's Success in Obesity Study
- Jan -27 - Jim Cramer on Novo Nordisk (NVO): ‘Be Careful’ Amid Trump Impact
- Jan -27 - NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
- Jan -27 - Novo Nordisk A/S - share repurchase programme
- Jan -27 - Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
- Jan -27 - 3 Intriguing Stocks That May Be Trading At An Estimated 13.8% Below Intrinsic Value
- Jan -25 - Why Novo Nordisk A/S (NVO) Surged on Friday
- Jan -25 - Is Novo Nordisk (NVO) the Best Stock to Buy and Hold for 2025?
- Jan -24 - Why Eli Lilly Stock Topped the Market Today
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Diabetes and Obesity Care
Expected Growth : 12 %
What the company do ?
Diabetes and Obesity Care from Novo Nordisk A/S provides innovative treatments and solutions for diabetes and obesity, improving patient outcomes and quality of life.
Why we expect these perspectives ?
Novo Nordisk's Diabetes and Obesity Care segment growth is driven by increasing prevalence of diabetes and obesity, growing demand for innovative treatments, and expanding access to healthcare in emerging markets. Additionally, the company's strong R&D pipeline, strategic partnerships, and effective commercialization strategies contribute to its 12% growth.
Segment n°2 -> Rare Disease
Expected Growth : 18 %
What the company do ?
Rare diseases from Novo Nordisk A/S refer to chronic and debilitating genetic disorders, such as haemophilia and Fabry disease, requiring lifelong treatment and care.
Why we expect these perspectives ?
Novo Nordisk's Rare Disease segment growth is driven by increasing demand for orphan drugs, expansion into emerging markets, and a strong pipeline of innovative treatments. The company's leadership in hemophilia and enzyme replacement therapies, as well as its strategic acquisitions, have further fueled growth. Additionally, growing awareness and diagnosis rates of rare diseases have contributed to the segment's 18% growth.
Novo Nordisk A/S Products
| Product Range | What is it ? |
|---|---|
| Ozempic | A glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes |
| Rybelsus | An oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes |
| Victoza | A glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes |
| Levemir | A long-acting insulin analog for the treatment of diabetes |
| NovoEight | A recombinant coagulation factor VIII for the treatment of hemophilia A |
| NovoSeven | A recombinant coagulation factor VIIa for the treatment of bleeding episodes in patients with hemophilia A or B |
Novo Nordisk A/S's Porter Forces
Threat Of Substitutes
Novo Nordisk A/S faces moderate threat from substitutes, as patients may opt for alternative treatments or lifestyle changes to manage their diabetes. However, the company's innovative products and strong brand recognition mitigate this threat.
Bargaining Power Of Customers
Patients and healthcare providers have limited bargaining power due to Novo Nordisk A/S's strong brand reputation and limited availability of alternative treatments.
Bargaining Power Of Suppliers
Novo Nordisk A/S has a diversified supplier base, reducing dependence on individual suppliers and minimizing the bargaining power of suppliers.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant R&D investments and regulatory hurdles, making it difficult for new entrants to compete with Novo Nordisk A/S.
Intensity Of Rivalry
The diabetes treatment market is highly competitive, with several established players, including Eli Lilly, Sanofi, and AstraZeneca, competing with Novo Nordisk A/S for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 20.22% |
| Debt Cost | 3.95% |
| Equity Weight | 79.78% |
| Equity Cost | 4.92% |
| WACC | 4.72% |
| Leverage | 25.34% |
Novo Nordisk A/S : Quality Control
Novo Nordisk A/S passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who … |
| UCB.BR | UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as … |
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
Vertex Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
GSK
A-Score
1-Year Total Return ->
4
Regeneron Pharmaceuticals
A-Score
1-Year Total Return ->
5
Novo Nordisk
A-Score
1-Year Total Return ->
6
